MaxWell Biosciences develops a synthetic immune system using its CLAROMER® platform, which creates small molecule compounds that mimic innate immune peptides to target a broad spectrum of pathogens. The technology addresses the decline of immune function associated with aging and aims to provide effective treatments for currently untreatable infectious diseases.
Funding
$15.6M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
The decline of immune function associated with aging, coupled with the rise of antibiotic-resistant pathogens, creates a critical need for new therapies to combat infectious diseases. Current treatments often struggle to address the broad spectrum of pathogens and may lead to resistance, leaving many infections untreatable.
Solution
MaxWell Biosciences is developing a synthetic immune system using its CLAROMER® platform to create small molecule compounds that mimic innate immune peptides. These compounds target a broad spectrum of pathogens, including bacteria, fungi, and viruses, without relying on traditional antibodies. Preclinical studies suggest the technology can reverse aspects of immunosenescence and provide a universal biodefense shield against known pathogens of pandemic concern. The CLAROMER® platform produces biostable, low molecular weight compounds that selectively target pathogen-specific phospholipids, disrupting the structure of infectious disease bugs.
Target Audience
The primary target audience includes individuals at risk of infectious diseases due to weakened immune systems, as well as healthcare providers seeking broad-spectrum anti-infective therapeutics.
Features
- CLAROMER® platform generates molecules that mimic the pathogen-agnostic core peptide of the innate immune system.
- Demonstrated efficacy against a broad spectrum of pathogens, including AMR bacteria, fungi, mold, yeast, pan-coronavirus, pan-influenza, pan-herpes, RSV, and Rhinovirus in preclinical studies.
- Selective targeting of pathogen-specific phospholipids, disrupting pathogen structure and function.
- Well-tolerated in animal and human tissues, with low toxicity at high dosages.
- Nasal spray formulation in development for airborne pathogens, with encouraging FDA feedback.
- Oral dosage form in early stages for gastrointestinal indications triggered by infectious pathogens and microbiome imbalance.